Amendments to the Claims:

This listing of claims will replace all other all prior versions, and listings, of claims in this application.

Listing of Claims:

1-10 (canceled)

11. (currently amended) A pharmaceutical composition comprising a solubilized therapeutic agent which is sparingly soluble in water, ~~excluding cyclosporins~~ said therapeutic agent selected from the group consisting of rapamycin, tacrolimus and mycophenolate-mofetil, and a carrier composition, said carrier composition consisting ~~essentially~~ of:

a) about 10-50% by weight, based on the carrier composition, of a co-surfactant which is substantially pure or which is in the form of a mixture, having a hydrophilic-lipophilic balance of less than 10 (HLB value according to Griffin), selected from the group consisting of polyglycerol fatty acid esters and sorbitan fatty acid esters;

b) about 5-40% by weight, based on the carrier composition, of a pharmaceutically acceptable oil which is substantially pure or which is in the form of a mixture, comprising a triglyceride as essential lipophilic component; and

c) about 10-50% by weight, based on the carrier composition, of a nonionic surfactant which is substantially pure or which is in the form of a mixture, having an HLB value of more than 10; and further optional pharmaceutically acceptable excipients.

12. (currently amended) A pharmaceutical composition of claim 11, comprising about l-30% by weight, based on the total weight of the carrier composition, of ~~a sparingly soluble~~ the therapeutic ~~agent having a solubility in pure water of less than 500 mg/1000 mL~~.

13. (canceled)

14. (previously presented) A pharmaceutical composition of claim 11, wherein component a) consists of a substantially pure polyglycerol fatty acid or of a mixture of different polyglycerol fatty acid esters, and the polyglycerol chain contains up to and

including 10 units of glycerol which are esterified with l-10 acid esters of saturated or unsaturated carboxylic acids having an even number of 8-20 carbon atoms.

15. (previously presented) A pharmaceutical composition of claim 11, wherein component a) contains as polyglycerol fatty acid substantially pure polyglyceryl 2-tetrastearate, polyglyceryl 3-monooleate, polyglyceryl 3-stearate, polyglyceryl 6-dioleate, polyglyceryl 6-distearate, polyglyceryl 10-dioleate, polyglyceryl 10-tetraoleate, polyglyceryl 10-decaoleate or polyglyceryl 10-decasterate, or a mixture of these compounds.

16. (previously presented) A pharmaceutical composition of claim 11, wherein component a) consists of a substantially pure sorbitan fatty ester, or of a mixture of sorbitan fatty esters, and the sorbitan skeleton is esterified with l-3 acid radicals of saturated or unsaturated carboxylic acids having an even number of 8-20 carboxylic atoms.

17. (previously presented) A pharmaceutical composition of claim 11, wherein component a) contains as sorbitan fatty acid ester substantially pure sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monoleate, sorbitan sesquioleate, or sorbitan trioleate, or a mixture of these compounds.

18. (previously presented) A pharmaceutical composition of claim 11, wherein component b) contains as pharmaceutically acceptable oil ground nut oil, sesame oil, sunflower oil, olive oil, corn oil, soybean oil, castor oil, cottonseed oil, rapeseed oil, thistle oil, grapeseed oil, fish oil or neutral oil, and component c) contains a nonionic surfactant with a hydrophilic component consisting of 15-60 units of ethylene oxide.

19. (currently amended) A pharmaceutical composition comprising[[:]] a solubilized therapeutic agent which is sparingly soluble in water[[;]], said therapeutic agent selected from the group consisting of rapamycin, tacrolimus and mycophenolate-mofetil, and a carrier composition, said carrier composition consisting ~~essentially~~ of:
(a) about 10-50% by weight, based on the carrier composition, of a co-surfactant having a hydrophilic-lipophilic balance of less than 10 (HLB value according to Griffin) which is a

substantially pure sorbitan fatty ester, or of a mixture of sorbitan fatty esters, and the sorbitan skeleton is esterified with l-3 acid radicals of saturated or unsaturated carboxylic acids having an even number of 8-20 carboxylic atoms;
b) about 5-40% by weight, based on the carrier composition, of a pharmaceutically acceptable oil which is substantially pure or which is in the form of a mixture, comprising a triglyceride as essential lipophilic component; and
c) about 10-50% by weight, based on the carrier composition, of a nonionic surfactant which is substantially pure or which is in the form of a mixture, having an HLB value of more than 10, wherein said nonionic surfactant is an amphiphilic substance whose hydrophilic component consists of polyethylene oxide.

20. (previously presented) The pharmaceutical composition of claim 19, wherein the polyethylene oxide component comprises 15 to 60 units of ethylene oxide.

21. (currently amended) A process for the preparation of a pharmaceutical composition of claim 11, which comprises mixing components a), b), and c) ~~and further optional pharmaceutically acceptable water-soluble excipients in any order~~, dispersing in this mixture the therapeutic agent which is sparingly soluble in water and, if desired, processing the dispersion to a suitable dosage form for oral administration.

22. (previously presented) A process of claim 21, which comprises filling the dispersion into starch or hard or soft gelatin capsules.